Moderna, Inc. (NASDAQ:MRNA) Stock Holdings Trimmed by Nuveen Asset Management LLC

Nuveen Asset Management LLC lessened its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 1.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 672,179 shares of the company's stock after selling 9,998 shares during the quarter. Nuveen Asset Management LLC owned about 0.17% of Moderna worth $27,949,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Norges Bank purchased a new position in Moderna in the fourth quarter worth approximately $163,833,000. FMR LLC grew its position in Moderna by 7.4% in the fourth quarter. FMR LLC now owns 18,664,634 shares of the company's stock worth $776,075,000 after acquiring an additional 1,282,469 shares during the period. Pictet Asset Management Holding SA grew its position in Moderna by 170.5% in the fourth quarter. Pictet Asset Management Holding SA now owns 1,766,398 shares of the company's stock worth $73,447,000 after acquiring an additional 1,113,455 shares during the period. Invesco Ltd. grew its position in Moderna by 24.3% in the fourth quarter. Invesco Ltd. now owns 5,006,462 shares of the company's stock worth $208,169,000 after acquiring an additional 979,858 shares during the period. Finally, Renaissance Technologies LLC lifted its stake in Moderna by 225.7% during the fourth quarter. Renaissance Technologies LLC now owns 1,010,758 shares of the company's stock worth $42,027,000 after purchasing an additional 700,458 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.

Moderna Price Performance

NASDAQ:MRNA traded down $0.24 during trading hours on Wednesday, reaching $26.52. 1,817,912 shares of the company traded hands, compared to its average volume of 8,011,779. The firm's 50-day moving average is $26.83 and its 200-day moving average is $34.20. The stock has a market cap of $10.26 billion, a P/E ratio of -2.86 and a beta of 1.99. Moderna, Inc. has a 1-year low of $23.15 and a 1-year high of $164.73.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, beating analysts' consensus estimates of ($2.92) by $0.40. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. The firm had revenue of $108.00 million for the quarter, compared to analysts' expectations of $130.35 million. During the same quarter in the prior year, the firm earned ($3.07) EPS. Moderna's quarterly revenue was down 35.3% on a year-over-year basis. As a group, research analysts predict that Moderna, Inc. will post -9.61 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on MRNA. JPMorgan Chase & Co. lowered their price target on Moderna from $33.00 to $26.00 and set an "underweight" rating for the company in a research report on Thursday, May 22nd. UBS Group lowered their price target on Moderna from $78.00 to $70.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Citigroup started coverage on Moderna in a report on Thursday, March 13th. They issued a "neutral" rating and a $40.00 target price for the company. Barclays decreased their target price on Moderna from $45.00 to $40.00 and set an "equal weight" rating for the company in a report on Friday, May 2nd. Finally, Morgan Stanley decreased their target price on Moderna from $39.00 to $32.00 and set an "equal weight" rating for the company in a report on Wednesday, April 9th. Four investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $53.58.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.